🇺🇸 Clenpiq in United States

FDA authorised Clenpiq on 28 November 2017 · 666 US adverse-event reports

Marketing authorisations

FDA — authorised 28 November 2017

  • Application: NDA209589
  • Marketing authorisation holder: FERRING PHARMS INC
  • Status: supplemented

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 185 reports (27.78%)
  2. Nausea — 102 reports (15.32%)
  3. Vomiting — 87 reports (13.06%)
  4. Diarrhoea — 59 reports (8.86%)
  5. Incorrect Dose Administered — 54 reports (8.11%)
  6. Headache — 50 reports (7.51%)
  7. Product Taste Abnormal — 34 reports (5.11%)
  8. Dizziness — 33 reports (4.95%)
  9. Malaise — 31 reports (4.65%)
  10. Product Packaging Difficult To Open — 31 reports (4.65%)

Source database →

Clenpiq in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Clenpiq approved in United States?

Yes. FDA authorised it on 28 November 2017; FDA has authorised it.

Who is the marketing authorisation holder for Clenpiq in United States?

FERRING PHARMS INC holds the US marketing authorisation.